Survodutide – 10mg

Survodutide

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

What Is Survodutide Peptide?

Survodutide (BI 456906) is a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed for laboratory research into obesity and type 2 diabetes metabolic pathways. Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.(link.springer.com)

Survodutide Peptide Benefits in Obesity Research

In diet-induced obese (DIO) mice, survodutide administration resulted in significant body weight reduction, comparable to or exceeding that of selective GLP-1R agonists. The compound also improved oral glucose tolerance and increased markers associated with energy expenditure, such as fibroblast growth factor 21 (FGF21) and hepatic nicotinamide N-methyltransferase (NNMT) mRNA expression. (pubmed.ncbi.nlm.nih.gov)

Survodutide 10mg: Glycemic Control and Dual Agonism

Further studies have shown that survodutide’s dual agonism leads to enhanced metabolic benefits. In diabetic db/db mice, survodutide treatment significantly lowered glycated hemoglobin levels, indicating improved glycemic control. The compound’s balanced activation of GCGR and GLP-1R pathways contributes to its robust anti-obesity and antidiabetic effects. (pubmed.ncbi.nlm.nih.gov)

Survodutide Peptide Dosage and Clinical Findings

A meta-analysis of clinical trials involving survodutide reported significant reductions in body weight, body mass index (BMI), and waist circumference among participants. Longer treatment durations and higher doses were associated with more pronounced effects, suggesting dose-dependent efficacy. (dmsjournal.biomedcentral.com)

Survodutide Peptide: Pharmacological Profile and Research Outlook

The pharmacological profile of survodutide, including its half-life extension through lipidation, allows for specific dosing intervals in long-term metabolic research protocols. Its dual receptor activity addresses multiple metabolic pathways, making it a promising candidate for comprehensive obesity and diabetes management. Buy survodutide from NuScience Peptides to support your research into dual GLP-1/glucagon receptor agonism, metabolic pathways, and weight management mechanisms. (researchgate.net)

In conclusion, survodutide’s dual GCGR/GLP-1R agonism offers a multifaceted approach to treating metabolic disorders. Its efficacy in preclinical models supports further investigation and development as a subject of investigation for obesity and metabolic disorder research.(researchgate.net)

References

1. Le Roux, Carel W., et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet Diabetes & Endocrinology, vol. 12, no. 3, 2024, pp. 162-173. https://pubmed.ncbi.nlm.nih.gov/38330987/
2. Zimmermann, Tina, et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes, Obesity and Metabolism, vol. 26, no. 1, 2024, pp. 1-12. https://pubmed.ncbi.nlm.nih.gov/38560764/
3. “Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: A meta-analysis.” Diabetology & Metabolic Syndrome, vol. 16, 2024, article 501. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-024-01501-x
4. Klein, Thomas, et al. “Perspectives in weight control in diabetes – Survodutide.” Diabetes Research and Clinical Practice, vol. 203, 2023, article 110123. https://www.sciencedirect.com/science/article/abs/pii/S0168822723005429
5. “Dose–response effects on HbA1c and bodyweight reduction of survodutide in type 2 diabetes: A phase II study.” Diabetologia, vol. 66, no. 1, 2023, pp. 53-65. https://link.springer.com/article/10.1007/s00125-023-06053-9

Survodutide peptide for sale at NuScience Peptides is supported by the peer-reviewed research referenced above, ensuring researchers can explore its dual-agonist metabolic effects with confidence.